|
|
News Breaks
|
August 11, 2011
|
| 07:10 EDT |  | MAPP |
| theflyonthewall.com: | MAP Pharma issued U.S. patent for methods of achieving rapid migraine relief | | MAP Pharmaceuticals announced that the U.S. Patent and Trademark Office, or USPTO, issued to the company U.S. Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The patent, which expires in 2028, results from the company's discovery that dihydroergotamine, or DHE, can be administered to achieve pharmacokinetic profiles that result in both rapid efficacy and minimal side effects. LEVADEX, which contains the company's proprietary formulation of DHE, is an orally inhaled investigational drug for the potential acute treatment of migraine in adults that targets the pharmacokinetic profiles described in this patent. :theflyonthewall.com |
|
|
News For MAPP From The Last 14 Days Check below for free stories on MAPP the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
